1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1324,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1324,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
Eletriptan reduces lost work time from migraine |
|
Inpharma Weekly,
Volume &NA;,
Issue 1324,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Antibacterial failure in newly treated UTIs |
|
Inpharma Weekly,
Volume &NA;,
Issue 1324,
2002,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1324,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Novel immunosuppressants on the horizon |
|
Inpharma Weekly,
Volume &NA;,
Issue 1324,
2002,
Page 7-9
Wendy McNeely,
Preview
|
|
摘要:
A number of novel immunosuppressants are in development for use in the prevention of organ transplant rejection. Some have demonstrated promising activity in preclinical and clinical studies to date, and it is hoped that they will have better efficacy and long-term tolerability than currently available agents such as cyclosporin and tacrolimus. The 2nd International Congress on Immunosuppression [ICIM;San Diego, US; December 2001] was opened by Dr Roy First from the University of Cincinnati Medical Center, US, who gave a summary of a handful of novel immunosuppressants, including FK 778, ISATX247, A 285222 and alemtuzumab.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1324,
2002,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1324,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
Letrozole superior to tamoxifen in advanced breast cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1324,
2002,
Page 11-12
Bob Carlson,
Preview
|
|
摘要:
The nonsteroidal aromatase inhibitor letrozole ['Femara'] demonstrated superiority over tamoxifen in the treatment of advanced breast cancer in postmenopausal women, in the final analysis of data from a pivotal phase III trial presented at the San Antonio Breast Cancer Symposium [SABCS;San Antonio, US; December 2001]. Median progression-free survival durations were 9.4 months for letrozole recipients, compared with 6 months for patients treated with tamoxifen. Objective response rates for letrozole and tamoxifen in this trial were 32 and 21%, respectively, and clinical benefit was observed in 50vs38% of patients. Another study presented at the SABCS meeting showed that the efficacy of letrozole was greater than that of tamoxifen in the neoadjuvant setting, irrespective of patients' ErbB (HER-2/neu) status. Based on the data presented at the meeting, researchers are recommending that letrozole be considered in preference to tamoxifen as a first-line therapy for postmenopausal women with advanced breast cancer.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1324,
2002,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|